Skip to content
Screener

Tandem Diabetes Care TNDM Q4 2025 Annual earnings

Reported February 19, 2026 · After market close

Revenue$290.4MBeat by $13.4M
EPS-$0.01Beat by $0.04
Revenue estimate$277.0M
EPS estimate-$0.05

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$266.1M
EPS estimate-$0.26

Financials

Q4 2025

Income statement

See full
Revenue$290.4M+2.7%
Gross profit$167.5M+6.4%
Operating income$8.3M+1,528%
Net income-$589.0K-178%
EPS (diluted)-$0.01-200%

Balance sheet

See full
Cash & equivalents$90.6M+30.9%
Total debt$444.5M-13.6%
Total equity$155.2M-41.0%
Total assets$881.1M-8.9%

Cash flow

See full
CapEx$6.7M+118%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.49B-37.0%
Enterprise value$1.84B-34.4%
P/S1.5×-1.0×

Profitability

See full
Gross margin53.8%+1.7pp
Operating margin-18.5%+55.5pp
Net margin-20.2%+795pp

Returns & leverage

See full
Return on equity-97.9%-202pp
Debt / equity2.9×+0.9×
Current ratio2.5×-0.4×

Segments

By product

See full
Supplies and other$150.3M+17.2%
Pump$140.1M+12.8%

FAQ

When did Tandem Diabetes Care report Q4 2025 earnings?
Tandem Diabetes Care (TNDM) reported Q4 2025 earnings on February 19, 2026 after market close.
What were Tandem Diabetes Care's Q4 2025 revenue and EPS?
Tandem Diabetes Care reported revenue of $290.4M and eps of $-0.01 for Q4 2025.
Did Tandem Diabetes Care beat estimates in Q4 2025?
Revenue beat the consensus estimate of $277.0M by $13.4M. EPS beat the consensus estimate of $-0.05 by $0.04.
How did Tandem Diabetes Care's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.7% from $282.6M a year earlier and eps grew 97.7% from $-0.44.
Where can I find Tandem Diabetes Care's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001438133-26-000009) and the 10-K periodic report (0001438133-26-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.